MedTrace Logo

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

NCT01251250 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-01-13

No results posted yet for this study

Summary

RATIONALE: Azadirachta indica may be an effective treatment for chronic lymphocytic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of Azadirachta indica in treating patients with chronic lymphocytic leukemia.

Conditions

  • Refractory Chronic Lymphocytic Leukemia
  • Stage II Chronic Lymphocytic Leukemia
  • Stage III Chronic Lymphocytic Leukemia
  • Stage IV Chronic Lymphocytic Leukemia

Interventions

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

western blotting

Correlative studies

GENETIC

gene expression analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

flow cytometry

Correlative studies

GENETIC

fluorescence in situ hybridization

Correlative studies

BIOLOGICAL

azadirachta indica

Given orally

GENETIC

reverse transcriptase-polymerase chain reaction

Correlative studies

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Asher Chanan-Khan · Roswell Park Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251250 on ClinicalTrials.gov